The goal of this clinical trial is to evaluate the dose response effect on cardiovascular disease risk factors of a Black Garlic Extract in subjects with Grade I Hypertension. The main questions it aims to answer are:

• If the reduction in blood pressure (systolic and diastolic) is in a dose-response manner
• If the changes in lipid profile are in a dose-response manner

Participants will be randomly assign to a low dose (250 mg/day), high dose (600 mg/day) or placebo of a standardized Garlic Extract (ABG+/GarlACE) during 12 weeks

Inclusion Criteria:

• Men and women with Grade I Hypertension (systolic blood pressure between 130 and 139 mmHg; and diastolic blood pressure between 80 to 89 mmHg) without taking any antihypertensive drug

Exclusion Criteria:

• Acute or chronic kidney disease including dyslipidemia due to nephrotic syndrome.- -
• Hypothyroidism
• Having previously suffered a myocardial infarction or stroke
• Pharmacological treatment with insulin, sulfonylureas, protease inhibitors
• Chronic gastrointestinal disease
• Pregnancy or intention to become pregnant during the study period.
• Breastfeeding
• Allergy or intolerance to garlic
• High alcohol consumption (>14 units per week)
• Smokers

No individual participant data will be available to other researchers. Group data could be asked by demand